USEF Announces Effective Date, Process for MPA Reporting

US Equestrian (USEF) announced Aug. 21 that Sept. 1 will serve as the effective start date for disclosure and reporting of horses that are being given medroxyprogesterone acetate (MPA), commonly known as Depo-Provera.

This is a follow-up to the announcement following US Equestrian’s Mid-Year Meeting and the Board of Director’s approval of the recommendation of the USEF MPA Panel.

Competitors are currently allowed to use MPA at USEF-licensed competitions. In an effort to better understand MPA use in horses competing at USEF-licensed competitions, officials will collect MPA disclosure forms. They hope this will allow them to collect data on pharmacokinetic data related to MPA administration, including how long it lasts in horses’ systems.

If a horse has received MPA and is competing at a USEF-licensed competition on Sept. 1 or thereafter, an MPA Disclosure Form must be completed. Forms must be completed on horses that received MPA 90 days or less before the effective date and which are competing on Sept..

Exhibitors will be able to locate the MPA disclosure form on the US Equestrian website, in both electronic and print versions. Additionally, an MPA Disclosure Form FAQ can be found online to assist with additional inquiries and questions.

It should be noted that an MPA disclosure form does not replace a medication report form (MRF). An MRF should be filled out separately for all other medications, according to USEF Drugs and Medications rules and regulations.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More